TiumBio Co., Ltd. (KOSDAQ:321550)
South Korea · Delayed Price · Currency is KRW 4,370.00
+15.00 (0.34%)
At close: Sep 4, 2026
TiumBio Revenue
TiumBio had revenue of 4.48B KRW in the quarter ending June 30, 2026, with 71.33% growth. This brings the company's revenue in the last twelve months to 15.00B, up 104.49% year-over-year. In the year 2025, TiumBio had annual revenue of 12.29B with 80.92% growth.
Revenue (ttm)
15.00B
Revenue Growth
+104.49%
P/S Ratio
8.75
Revenue / Employee
n/a
Employees
n/a
Market Cap
131.27B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 12.29B | 5.50B | 80.92% |
| Dec 31, 2024 | 6.79B | 1.89B | 38.65% |
| Dec 31, 2023 | 4.90B | -4.22B | -46.27% |
| Dec 31, 2022 | 9.12B | 9.06B | 15,952.75% |
| Dec 31, 2021 | 56.80M | -992.15M | -94.59% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Cell Biotech | 60.40B |
| ISU Abxis | 51.04B |
| Choong Ang Vaccine Laboratory | 39.19B |
| Genome & Company | 24.46B |
| NIBEC | 22.60B |
| CORESTEMCHEMON | 18.29B |
| Prestige Biologics | 18.03B |
| Bio Solution | 17.39B |